[ad_1]
Researchers have discovered that a "toxic antibody" is the last weapon capable of treating several forms of advanced cancer.
The new drug, called "Trojan Horse" for chemotherapy, has proved worthy of going from a series of clinical trials to a series of tests on various patients. It's the closest treatment we can get right now.
Scientists from the Cancer Research Institute in London and the Real Marsden Foundation of the National Institutes of Health have tested the new treatment in a clinical trial involving 147 patients, to assess its potential benefits and its risk of side effects.
Tisotumab vedotin (TV) consists of a monoclonal antibody and a cytotoxic component capable of killing killer cells.
Scientists are also looking for cancer treatment in Antarctica
"It's exciting that this mechanism is completely new – it acts like a Trojan horse to infiltrate cancer cells and kill them from within," says Johan de Bono, an oncologist with the Institute for Cancer Research. "Our first study showed that it could potentially treat a large number of different cancers, especially those with low survival rates."
The study focused on cervical cancer, bladder, ovaries, endometrium, esophagus and lung.
People with bladder cancer have the most answers, with 27% of registered volunteers. On the other hand, endometrial cancer was the least improved by 7%
Progress has been slow, with the first phase of clinical trials starting in 2013 with a television safety test of only 27 patients. A year and a half later, serious health triggers emerged. , including severe type 2 diabetes, inflammation of the mucous membranes and fever.
Doping doses also have side effects such as nosebleeds, nausea and fatigue.
However, when it comes to life or death, non-fatal diseases like this seem innocuous. In Phase II, the results showed that treatment could make a big difference in patients with advanced cancer.
"We urgently need innovative treatments, such as those that can fight cancer in new ways and remain effective even against tumors that have become resistant to therapeutic standards," said Paul Warkman, executive director of the Institute. cancer research.
[ad_2]
Source link
